Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium sulfacetamide is a sulfonamide antibiotic small molecule marketed by BioComp Pharma as a generic topical treatment for various dermatological conditions. It functions as a bacteriostatic agent by competitively inhibiting the bacterial enzyme dihydropteroate synthase (DHPS). This action prevents the incorporation of para-aminobenzoic acid (PABA) into dihydropteroic acid, thereby disrupting the synthesis of bacterial folic acid, which is essential for nucleic acid production. BioComp Pharma provides sodium sulfacetamide in several topical dosage forms, including cleansers, lotions, and washes, typically at a 10% concentration. These products are primarily indicated for the treatment of acne vulgaris, acne rosacea, and seborrheic dermatitis. While sodium sulfacetamide is also utilized in ophthalmic formulations for bacterial eye infections, BioComp's portfolio is centered on dermatologic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfacetamide.